Compare ES & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ES | ILMN |
|---|---|---|
| Founded | 1927 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | ES | ILMN |
|---|---|---|
| Price | $68.04 | $134.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 15 |
| Target Price | $71.25 | ★ $114.93 |
| AVG Volume (30 Days) | ★ 3.0M | 1.6M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 3.65 | ★ 4.46 |
| Revenue | ★ $13,148,536,000.00 | $4,288,000,000.00 |
| Revenue This Year | $10.10 | N/A |
| Revenue Next Year | $4.11 | $2.08 |
| P/E Ratio | ★ $18.69 | $30.24 |
| Revenue Growth | ★ 13.12 | N/A |
| 52 Week Low | $52.28 | $68.70 |
| 52 Week High | $75.25 | $153.06 |
| Indicator | ES | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 69.62 |
| Support Level | $67.06 | $126.44 |
| Resistance Level | $68.84 | $129.72 |
| Average True Range (ATR) | 1.10 | 3.59 |
| MACD | 0.28 | 0.08 |
| Stochastic Oscillator | 81.68 | 85.06 |
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.